WHAT IS OUR INVESTMENT CASE?
In becoming the trusted global leader in access to medicines, the Group has consistently delivered healthy financial returns. We believe there are several reasons to invest in Clinigen.
We offer access to medicines at the key stages of the pharmaceutical product lifecycle by utilising Clinigen’s balanced portfolio, across the services and products businesses.
We have organically built a global supply chain and distribution network, organically, through acquisitions and partnerships, providing local market knowledge supported by global expertise.
|COUNTRIES SUPPLIED IN LAST THREE YEARS||127|
We have an experienced management team both at the regional and Group level, with a track record of delivering strong growth every year since inception.
We are the global leader in the management of early access programs to innovative new medicines. We are a global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials (‘IITs’).
We have made a number of acquisitions, both of corporates to build out the infrastructure platform, and of niche hospital speciality medicines. Both have contributed towards double-digit EPS growth since IPO in 2012.
|CORPORATE ACQUISITIONS SINCE IPO IN 2012||6|
|PRODUCT ACQUISITIONS SINCE IPO IN 2012||6|
We have deep, well-established relationships with pharmaceutical and biotech companies as clients and Healthcare professionals (‘HCPs’) as customers.
|NUMBER OF PHARMACEUTICAL AND BIOTECH COMPANIES AS CLIENTS||557|
|HCPS AS CUSTOMERS*||18,625|
*HCPs as customers indicates the number of registered users on Cliniport
We have a significant exposure to emerging pharmaceutical growth markets from building out our infrastructure platform, service capability and product offering through a combination of organic and acquisitional growth.
We generate strong cash returns which are underpinned by strong credit control and working capital management.
2. Operating cash flow is net cash flow from operating activities before income taxes and interest.